BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-126@catalystbrief.girapphe.com
DTSTAMP:20261117T181557Z
LAST-MODIFIED:20261117T181557Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Shanghai Chia Tai Tianqing Pharmaceutical Technology Devel
 opment Co.\, Ltd. — TQC2731 injection [Mar 2027]
DESCRIPTION:Phase 3 primary completion: Clinical Trial of TQC2731 Injection
  in Patients With Chronic Sinusitis and Nasal Polyps.\nSource: https://cli
 nicaltrials.gov/study/NCT07107256\nhttps://catalystbrief.girapphe.com/e/12
 6?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/126?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
